BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 23625339)

  • 1. Development of an Epstein-Barr virus-associated lymphoproliferative disorder in a patient treated with azacitidine for chronic myelomonocytic leukaemia.
    Menter T; Schlageter M; Bastian L; Haberthür R; Rätz Bravo AE; Tzankov A
    Hematol Oncol; 2014 Mar; 32(1):47-51. PubMed ID: 23625339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent classical Hodgkin lymphoma and plasmablastic lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with fludarabine: a dimorphic presentation of iatrogenic immunodeficiency-associated lymphoproliferative disorder with evidence suggestive of multiclonal transformability of B cells by Epstein-Barr virus.
    Foo WC; Huang Q; Sebastian S; Hutchinson CB; Burchette J; Wang E
    Hum Pathol; 2010 Dec; 41(12):1802-8. PubMed ID: 20869749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
    Beguin Y; Selleslag D; Meers S; Graux C; Bries G; Deeren D; Vrelust I; Ravoet C; Theunissen K; Voelter V; Potier H; Trullemans F; Noens L; Mineur P
    Acta Clin Belg; 2015 Feb; 70(1):34-43. PubMed ID: 25444072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasmacytic hyperplasia in age-related Epstein-Barr virus-associated lymphoproliferative disorders: a report of two cases.
    Kojima M; Morita Y; Nakamura N; Shimizu K; Murayama K; Nakamura S
    Pathol Res Pract; 2008; 204(4):267-72. PubMed ID: 18187262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posttransplant lymphoproliferative disorder in pediatric bone marrow transplant recipients: disseminated disease of donor origin demonstrated by fluorescence in situ hybridization.
    Lones MA; Lopez-Terrada D; Shintaku IP; Rosenthal J; Said JW
    Arch Pathol Lab Med; 1998 Aug; 122(8):708-14. PubMed ID: 9701332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatal non-transplant-related epstein-barr virus-associated atypical lymphoid proliferations in infants and children: a clinicopathologic study.
    Salama ME; Parham DM; Perkins SL; Bahler DW; Ellison DA
    Pediatr Dev Pathol; 2008; 11(6):443-9. PubMed ID: 18473605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation].
    Liu QF; Fan ZP; Luo XD; Zhang Y; Sun J
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(44):3123-6. PubMed ID: 19159594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fulminant Epstein-Barr virus (EBV)-associated T-cell lymphoproliferative disorder with hemophagocytosis following autologous peripheral blood stem cell transplantation for relapsed angioimmunoblastic T-cell lymphoma.
    Awaya N; Adachi A; Mori T; Kamata H; Nakahara J; Yokoyama K; Yamada T; Kizaki M; Sakamoto M; Ikeda Y; Okamoto S
    Leuk Res; 2006 Aug; 30(8):1059-62. PubMed ID: 16330097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus (EBV)-associated post-transplantation lymphoproliferative disorder simultaneously affecting both B and T cells after allogeneic bone marrow transplantation.
    Chuhjo T; Yachie A; Kanegane H; Kimura H; Shiobara S; Nakao S
    Am J Hematol; 2003 Apr; 72(4):255-8. PubMed ID: 12666136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus-positive cytotoxic T-cell lymphoma followed by chronic active Epstein-Barr virus infection-associated T/NK-cell lymphoproliferative disorder: a case report.
    Kato S; Miyata T; Takata K; Shimada S; Ito Y; Tomita A; Elsayed AA; Takahashi E; Asano N; Kinoshita T; Kimura H; Nakamura S
    Hum Pathol; 2013 Dec; 44(12):2849-52. PubMed ID: 24012167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation.
    Liu QF; Fan ZP; Luo XD; Sun J; Zhang Y; Ding YQ
    Transpl Infect Dis; 2010 Aug; 12(4):284-91. PubMed ID: 20345506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HHV-8+, EBV+ multicentric plasmablastic microlymphoma in an HIV+ Man: the spectrum of HHV-8+ lymphoproliferative disorders expands.
    Seliem RM; Griffith RC; Harris NL; Beheshti J; Schiffman FJ; Longtine J; Kutok J; Ferry JA
    Am J Surg Pathol; 2007 Sep; 31(9):1439-45. PubMed ID: 17721201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
    van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
    Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review.
    Thorpe M; Montalvão A; Pierdomenico F; Moita F; Almeida A
    Leuk Res; 2012 Aug; 36(8):1071-3. PubMed ID: 22607959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).
    Wehmeyer J; Zaiss M; Losem C; Schmitz S; Niemeier B; Harde J; Hannig CV; Harich HD; Müller J; Klausmann M; Tessen HW; Potthoff K
    Eur J Haematol; 2018 Dec; 101(6):766-773. PubMed ID: 30091166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of azacitidine in chronic myelomonocytic leukemia.
    Costa R; Abdulhaq H; Haq B; Shadduck RK; Latsko J; Zenati M; Atem FD; Rossetti JM; Sahovic EA; Lister J
    Cancer; 2011 Jun; 117(12):2690-6. PubMed ID: 21656746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectiveness of azacitidine in chronic myelomonocytic leukemia harboring del(20q) - a case report].
    Manabe M; Okita J; Takakuwa T; Harada N; Aoyama Y; Kumura T; Ohta T; Furukawa Y; Mugitani A
    Gan To Kagaku Ryoho; 2014 Jun; 41(6):781-4. PubMed ID: 25129095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactive Epstein-Barr virus-related polyclonal lymphoproliferative disorder in a patient with AIDS.
    Martin SI; Zukerberg L; Robbins GK
    Clin Infect Dis; 2005 Oct; 41(8):e76-9. PubMed ID: 16163622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine.
    Adès L; Sekeres MA; Wolfromm A; Teichman ML; Tiu RV; Itzykson R; Maciejewski JP; Dreyfus F; List AF; Fenaux P; Komrokji RS
    Leuk Res; 2013 Jun; 37(6):609-13. PubMed ID: 23415110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EBV-associated B- and T-cell posttransplant lymphoproliferative disorders following primary EBV infection in a kidney transplant recipient.
    Yin CC; Medeiros LJ; Abruzzo LV; Jones D; Farhood AI; Thomazy VA
    Am J Clin Pathol; 2005 Feb; 123(2):222-8. PubMed ID: 15842046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.